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Docetaxel in Combination with Either Cisplatin or
Gemcitabine in Unresectable Non-small Cell Lung
Carcinoma: A Randomized Phase II Study by the Japan
Lung Cancer Cooperative Clinical Study Group
Nobuyuki Katakami, MD, PhD,* Yuichi Takiguchi, MD, PhD,† Kozo Yoshimori, MD, PhD,‡
Hiroshi Isobe, MD, PhD,§ Akihiro Bessho, MD, PhD, Akinobu Yoshimura, MD, PhD,¶
and Hisanobu Niitani, MD, PhD**
Purpose: To evaluate whether cisplatin-free chemotherapy (do-
cetaxel and gemcitabine [DG]) provides a comparable alternative to
cisplatin-based chemotherapy (docetaxel and cisplatin [DC]) as
first-line treatment for patients with advanced non-small cell lung
cancer (NSCLC).
Patients and Methods: Patients (n  133) with stage IIIB to IV
NSCLC were randomly assigned to receive DG (docetaxel 60
mg/m2, day 8  gemcitabine 800 mg/m2, days 1 and 8, every 3
weeks; n  65) or DC (docetaxel 60 mg/m2, day 1  cisplatin 80
mg/m2, day 1, every 3 weeks; n 68). The primary end point of the
study was overall response rate. No prophylactic use of human
recombinant granulocyte colony stimulating factor was allowed.
Results: The planned patient number was 150. However, an unex-
pectedly high incidence of grade 3 interstitial lung disease (11.1%)
was identified in the DG arm, so the study was closed early. The
overall response rates of the DG and DC arms were 27% and 23.5%,
respectively, which demonstrated that the DG treatment was not
inferior to the DC arm. Gastrointestinal toxicities were less frequent
in the DG arm than in DC arm. Interstitial lung disease was
exclusively observed in seven of 63 patients in the DG arm (11.1%).
Median survival and 1-year survival rate were comparable between
the two arms (median survival, DG 13.7 months versus DC 11.4
months; 1-year survival, DG 56.6% versus DC 47.7%).
Conclusion: The DG regimen has a response rate and survival rate
comparable to those of the DC regimen and can therefore be
considered from an efficacy point of view to be comparable. How-
ever, the DG regimen may have induced pulmonary toxicity in 11%
of the patients exposed and therefore should be used cautiously
among patients with advanced NSCLC.
Key Words: Docetaxel, Gemcitabine, Cisplatin, Combination che-
motherapy, First-line, Advanced non-small cell lung cancer, Ran-
domized phase II Study.
(J Thorac Oncol. 2006;1: 447–453)
Lung cancer ranks among the most commonly occurringmalignancies and currently is the leading cause of cancer-
related deaths in industrialized countries all around the world.
In Japan, lung cancer is the most common cause of cancer-
related deaths in men and the second most common cause of
cancer-related deaths in women, with an incidence of 44 per
100,000 individuals. Approximately 55,000 Japanese died
from this disease in 2001. Non-small cell lung cancer
(NSCLC) represents approximately 80% to 85% of cases of
lung cancer. The prognosis of patients with this cancer is
poor: two-thirds are inoperable, and the overall 5-year sur-
vival is less than 15%. These inoperable patients are potential
candidates for systemic chemotherapy. Meta-analyses of tri-
als comparing systemic chemotherapy with best supportive
therapy in advanced NSCLC concluded that chemotherapy
could prolong survival by a modest but statistically signifi-
cant period.1–5
In the1990s, several new anti-cancer agents such as
irinotecan (CPT-11), docetaxel (DTX), paclitaxel (PTX),
gemcitabine (GEM), and vinorelbine (VNR) demonstrated
promising antitumor activity against NSCLC, with docu-
mented responses ranging from 13% to 27%.6 Among these
agents, DTX a semisynthetic taxoid derived from the Euro-
pean yew Taxus baccata, is used for treating patients with
advanced NSCLC, either in combination with other chemo-
therapeutic agents or as a single agent.7–10 DTX is often used
in combination with platinum-based chemotherapeutic
agents. A four-arm randomized study, ECOG 1594, evaluated
DTX  cisplatin (CDDP), GEM  CDDP, and PTX 
carboplatin (CBDCA) against a control arm of PTX 
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CDDP, to reveal comparable clinical outcome of the three
experimental arms with the control.11 Another randomized
study, TAX326, showed a superior response rate and survival
benefit of DTX  CDDP compared with VNR  CDDP, but
no superiority of DTX CBDCA over the control arm (VNR
 CDDP).12 In addition, in the TAX-JP301study in Japan,
DTX (60 mg/m2, day1)  CDDP (80 mg/m2, day 1) was
proven to have a response rate and survival benefit superior to
a control arm of vindesine (VDS)  CDDP.13 Therefore, the
DTX  CDDP regimen is now considered a standard for the
treatment of advanced NSCLC.
GEM is a difluorinated analogue of deoxycytidine re-
sembling cytalabine and an active agent for NSCLC, either in
combination or as a single agent.14–16 Phase II and III studies
of DTX  GEM have demonstrated equivalent responses to
DTX  CDDP.17–19 A phase I/II study of DTX  GEM gave
promising results in Japan with a recommended regimen of
GEM 800 mg/m2 on days 1 and 8 plus docetaxel 60 mg/m2 on
day 8. The overall response rate was 43.9%, and the median
survival time was 11.8 months.20
The purpose of the present study was to assess the
efficacy of the DTX  GEM (DG) regimen and to determine
whether it is comparable to the DTX CDDP (DC) regimen.
The primary end point was response rate, and the secondary
end points were 1-year survival rate and toxicity.
PATIENTS AND METHODS
Eligibility Criteria
The eligibility criteria for study entry included histo-
logically or cytologically confirmed stage IIIB or IV NSCLC,
no prior therapy, the presence of a measurable lesion by
Response Evaluation Criteria In Solid Tumors (RECIST), age
20 to 75 years, an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0 or 1, adequate baseline
organ function (defined as 4,000/L  WBC 12,000/L,
neutrophils 2000/L, platelets 100,000/L, hemoglobin
 9.5 g/dL, serum transaminase levels  2.5 times the upper
limit of normal, bilirubin  upper limit of normal, creatinine
 upper limit of normal), creatinine clearance 60 mL/min,
PaO2 70 Torr, a life expectancy of at least 3 months, and
written informed consent. The study was conducted accord-
ing to the Helsinki Declaration and was approved by the
ethics committees of the participating centers. Patients with
the following criteria were excluded from the study: intersti-
tial pneumonia (pulmonary fibrosis) manifest on chest radio-
graph and pulmonary symptom (non-productive cough or
dyspnea on exertion), uncontrolled complications of heart or
liver, diabetes mellitus, bleeding, peripheral neuropathy of
grade 2 or worse, symptomatic brain metastases, active con-
comitant malignancy, pregnancy, breast feeding, myocardial
infarction within 3 months, or other conditions rendering the
patient unsuitable for this study.
Treatment Plan
Patients were randomly allocated to receive DC or DG
stratified by study center, disease stage (IIIB or IV) and sex.
Patients were randomly assigned to receive at least two cycles
of DC or DG every 21 days (Fig. 1). Patients in the control
arm (DC) received DTX 60 mg/m2 IV (in 250 mL of 5%
glucose over 1 hour), and CDDP 80 g/m2 (in 500 mL of
normal saline over 1 hour) IV on day 1. Although docetaxel
is usually administered as a 75-mg/m2 dose, Okamoto et al.21
demonstrated that a response rate of 42% could be achieved
when 60 mg/m2 DTX and 80 mg/m2 CDDP were adminis-
tered to patients with stage IV NSCLC. Patients on the DG
arm received DTX 60 mg/m2 IV (in 250 mL of 5% glucose
over 1 hour) on day 8, and GEM 800 mg/m2 IV (in 100 mL
of 5% glucose over 30 minutes) on days 1 and 8. Dexameth-
asone, 5-hydroxytryptamine-3 receptor antagonists, diphen-
hydramine, and ranitidine were given before chemotherapy
for antiemetic and hypersensitivity prophylaxis. Patients re-
ceived at least two courses of treatment unless disease pro-
gression or unacceptable toxicity was documented. Respond-
ers or patients without disease progression continued
treatment until the appearance of progressive disease or major
toxicity. Recombinant human granulocyte colony-stimulating
factor (G-CSF) was administered when National Cancer In-
stitute Common Toxicity Criteria grade 3 to 4 leukopenia or
neutropenia occurred. However, G-CSF was not used prohy-
lactically.
Treatment of day 8 GEM in the DG arm was delayed
until recovery (no longer than 1 week) if the neutrophil count
decreased 1,500/L and/or the platelet count was
100,000/L and if non-hematological toxicities were 
grade 2, excluding those caused by nausea/vomiting and
alopecia. If recovery was delayed longer than 1 week, the
dose of GEM was omitted. Two weeks’ delay of initiation of
the subsequent course was allowed; otherwise, the patient
was withdrawn from the study. Treatment was discontinued
in the event of grade 3 neuropathy or if infection developed.
Dose reduction of any of the drugs was not allowed during
the subsequent treatment cycle in both arms. Use of thoracic
or other radiotherapy after completion of chemotherapy and
use of second-line chemotherapy were left to the discretion of
treating clinicians.
Patient Evaluation
Patients were assessed at baseline and at each admin-
istration of chemotherapy, then every 4 weeks for the first
year and thereafter at 8-week intervals. Assessments at base-
line and during treatment included history and physical ex-
FIGURE 1. Outline of the study.
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amination (including weight and height), ECOG performance
status, blood chemistry, and full blood count. Minimal base-
line imaging consisted of chest radiograph; thoracic, abdom-
inal, and brain CT scans; and isotope bone scan. Toxicities
were assessed according to National Cancer Institute Com-
mon Toxicity Criteria after each cycle (version 2.0, revised
1994). Patients were evaluated for response at the start of
each cycle by CT scan, which was repeated every 4 weeks.
RECIST criteria were used to define response.22 An extramu-
ral review was conducted to validate the eligibility of the
patients, staging, responses, and toxicities. Disease status and
any additional anticancer treatment were reported at each
follow-up visit.
Statistical Considerations
The primary end point was response rate, and non-
inferiority was the basis of the hypothesis to be tested. Parity
could be concluded if the lower boundary of the 90% confi-
dence interval of the difference of the response rates between
two treatment arms was greater than 20%.23 The expected
response rate for each arm was 33%. The planned sample size
of 69 patients per treatment group provided the study with
80% power to detect a difference of response rate of two arms
with a type I error of 0.05 (one-sided). We compared Kaplan-
Meier curves for overall survival and progression-free sur-
vival using the standard log-rank test. Tumor responses in
both groups were compared using Fisher’s exact test. Other
categorical data, such as treatment data and incidence of
adverse events, were compared between treatment groups
using the 2 test. All analyses were performed on an inten-
tion-to-treat basis except for the analyses of response and
toxicity. All P values are two-sided.
RESULTS
Patient Characteristics
From May 2002 until October 2003, 133 previously
untreated patients were recruited for the study from 24
centers of the Japan Lung Cancer Cooperative Clinical Study
Group and were randomly assigned to treatment in the trial
(Fig. 1). The planned patient number was 150 (75 in each
arm). However, an unexpected high incidence of grade 3
interstitial lung disease (ILD) was identified exclusively in
DG arm by the Adverse Event Reporting system. The prin-
cipal investigator stopped the enrollment into the trial on
September 30, 2003. The Safety Committee reviewed the
investigator’s report and recommended that the Japan Lung
Cancer Cooperative Clinical Study Group terminate the study
immediately because of lung injury in the DG arm.
Two patients in the DG arm did not receive any
protocol treatment. One patient suffered from uncontrollable
atrial fibrillation, and the investigator decided against this
patient receiving protocol treatment. The other patient had a
massive hematemesis from a gastric cancer that was discov-
ered after enrollment (second primary). Because two patients
were deemed ineligible, 131 patients were evaluated for
survival, response, and toxicity. The characteristics of eligi-
ble patients are listed in Table 1.
Treatment Delivery
The median number of treatment cycles delivered was
2.0 for the DC arm and 3.0 for the DG arm (Table 2).
Fifty-two patients (76%) in the DC arm and 54 patients (86%)
in the DG arm received at least two cycles of chemotherapy.
The main reasons for treatment discontinuation before the
second cycle in the DC and DG arms, respectively, were
disease progression (8.8% vs 7.9%), adverse event (8.8% vs
4.8%), and adverse event with withdrawal of consent (5.9%
vs 1.6%) Table 2.
Response
There were 16 partial responses with an overall re-
sponse rate of 23.5% (95% CI, 13.5–33.6%) in the DC arm.
The DG arm had 17 partial responses, with an overall re-
sponse rate of 27.0% (95% CI, 16.0–37.9%) (Table 3).
Because the difference of the response rate between two
treatment arms was 3.5% (90% confidence interval, 9.0 to
16.0%) and the lower bound of the 90% confidence interval








M 86 (65.6) 45 (66.2) 41 (65.1) NS
F 45 (34.4) 23 (33.8) 22 (34.9)
Age
Median (range) 63 (31-75) 65 (31-75) 61 (49-75)
 65 yr 74 (56.5) 33 (48.5) 41 (65.1) P  0.0832
 65 yr 57 (43.5) 35 (51.5) 22 (34.9)
Performance status
0 61 (46.6) 32 (47.1) 29 (46.0) NS
1 70 (53.4) 36 (52.9) 34 (54.0)
Stage
IIIB 34 (26.0) 18 (26.5) 16 (25.4) NS
IV 97 (74.0) 50 (73.5) 47 (74.6)
Histological type
Adeno carcinoma 87 (66.4) 46 (67.6) 41 (65.1)
Squamous 36 (27.5) 18 (26.5) 18 (28.6) NS
Others 8 (6.1) 4 (5.9) 4 (6.3)
Ineligible after
treatment
2 (1.5) 1 (1.5) 1 (1.5)
2 test (Yates).
Values are n (%) or n (range).
TABLE 2. Courses administered






Median Two courses Three courses
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was not lower than 20%, it was demonstrated that the DG
regimen was not inferior to the DC regimen.
Survival
The median overall survival was 11.4 months for the
DC arm and 13.7 months for the DG arm.
The hazard ratio was 0.822 (95% CI, 0.531–1.271).
One-year survival rate was 47.7% versus 56.6% in the DC
and DG arms, respectively (Fig 2).
Toxicity
No differences were seen among the two treatment
groups with regard to grade 3 to 4 neutropenia, febrile
neutropenia, leukocytopenia, thrombocytopenia, or anemia
(Table 4). Grade 3 lung toxicity occurred exclusively in the
DG arm. Seven patients in the DG arm (one woman [4.5%]
and eight men [14.6%]) had grade 3 ILD, and all patients
were treated successfully with the intravenous administration
of high-dose methylpredonisolone and oxygen therapy (Table
5). The occurrence of Grade 3 pneumonitis in the first four
patients occurred between April and June 2003; patients
recovered to grade 1 or 2 with appropriate treatment. Another
two cases of Grade 3 pneumonitis occurred in September
2003, at which time the Safety Committee recommended
early termination of the trial because of lung injury in the DG
arm. Therefore, this trial was terminated early, on October 13,
2003. Another patient developed grade 3 pneumonitis after
three courses of chemotherapy in November 2003. Interstitial pneumonitis occurred after two courses of
chemotherapy in six of seven patients; most cases occurred in
the third course of therapy. All the patients presented with the
acute onset of dyspnea, sometimes associated with cough or
low-grade fever. High-resolution CT scans typically showed
bilateral diffuse ground glass opacities and mild thickening of
interstitial septa. No infectious agents were identified in the
blood, sputum, or broncho-alveolar lavages in any of these
patients, and there was no response to antibiotics.
A higher percentage of patients in the DC arm experi-
enced grade 3 or 4 diarrhea, nausea and vomiting, and
appetite loss compared with patients in the DG arm. No
treatment-related death was observed in either treatment arm.
Second-Line Treatment
After discontinuation or completion of the study, the
number of patients who received second-line therapy and the
nature of the second-line therapy were well balanced between
TABLE 3. Tumor response
Total (n  131) DC arm (n  68) (%) DG arm (n  63) (%)
CR 0 0 0
PR 33 (25.2) 16 (23.5) 17 (27.0)
SD 78 (59.5) 42 (61.8) 36 (57.1)
PD 16 (12.2) 9 (13.2) 7 (11.1)
NE 4 (3.1) 1 (1.5) 3 (4.8)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NE, no evidence of disease.
95% confidence interval of response rate: DC 13.5%–33.6%; DG 16.0%–37.9%.
90% confidence interval of difference (2  3.5%) of response rate 9.0% to
16.0%.
FIGURE 2. Survival curves according to regimen.







Neutropenia (Grade 3, 4) 64.1 63.2 65.1
(32.8, 31.3) (25.0, 38.2) (41.3, 23.8)
Febrile neutropenia (Grade 3, 4) 12.2 10.3 14.3
(9.9, 2.3) (7.4, 2.9) (12.7, 1.6)
Leukocytopenia (Grade 3, 4) 41.2 42.6 39.7
(35.9, 5.3) (33.8, 8,8) (38.1, 1.6)
Thrombocytopenia (Grade 3, 4) 3.8 1.5 6.3
(3.8, 0.0) (1.5, 0.0) (6.3, 0.0)
Anemia (Grade 3, 4) 4.6 7.4 1.6
(3.8, 0.8) (5.9, 1.5) (1.6, 0.0)
Values are expressed as percentages. P  not significant (Fisher’s exact test).







Lung injury 5.3 0.0 11.1 P  0.0050*
(Grade 3, 4) (5.3, 0.0) (0.0, 0.0) (11.1, 0.0)
Hepatic dysfunction 3.1 4.4 1.6 NS
(Grade 3, 4) (2.3, 0.8) (2.9, 1.5) (1.6, 0.0)
Diarrhea 4.6 8.8 0.0 P  0.0284
(Grade 3, 4) (4.6, 0.0) (8.8, 0.0) (0.0, 0.0)
Nausea/vomiting 13.7 20.6 6.3 P  0.0222
(Grade 3, 4) (13.7, 0.0) (20.6, 0.0) (6.3, 0.0)
Appetite loss 19,8 29.4 9.5 P  0.0046
(Grade 3, 4) (18.3, 1.5) (26.5, 2.9) (9.5, 0.0)
Fever not related to 6.9 2.9 11.1 NS
neutropenia
(Grade 3, 4)
(6.9, 0.0) (2.9, 0.0) (11.1, 0.0)
Edema 0.8 0.0 1.6 NS
(Grade 3, 4) (0.8, 0.0) (0.0, 0.0) (1.6, 0.0)
Values are expressed as percentages.
NS, not significant.
P values obtained using Fisher’s exact test.
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the groups. In total, 102 patients (77.9%) went on to receive
additional chemotherapy, including gefitinib (DC, 72.1%;
DG, 84.1%), and 38 patients (29.0%) received radiotherapy
(DC, 27.9%; DG, 30.2%). The most common second-line
chemotherapy was gefitinib monotherapy, and there was no
difference in the proportion of patients who received gefitinib
between the two arms (DC, 32.4%; DG, 30.2%).
DISCUSSION
In the present article, we describe the randomized phase
II trial of DTX CDDP (DC) and DTX  GEM (DG) in the
treatment of chemotherapy-naı¨ve patients with advanced
NSCLC. The response rates were comparable in each arm
(DC; 23.5%, DG; 27.0%), which demonstrates that the DG
regimen was not inferior to the DC regimen with respect to
response rate. This was also the case for the median survival
time and 1-year survival rate (13.7 months and 56.6%, re-
spectively, for the DG arm versus 11.4 months and 47.7%,
respectively, for the DC arm). These observations might
suggest that non–platinum-based chemotherapy doublets in-
corporating newer anticancer drugs have activity similar to
that of platinum-based doublets in terms of overall survival
and response rate. The reason why the survival rate of our
trial seems to be better than often reported for this population
of patients (i.e., median survival of 8-10 months) may be the
use of second-line treatment with gefitinib. An international
randomized phase II trial among patients with advanced or
metastatic NSCLC after platinum-based chemotherapy dem-
onstrated a response rate of 28% in the Japanese population.24
As 32.4% of patients in DC arm and 30.2% of patients in DG
arm received gefitinib, this may explain the apparently better
overall survival in our study.
Three other studies have evaluated the combination of
DTX and GEM in randomized trials. In their study of 441
patients, Georgoulias et al.19 reported that DC (DTX 100
mg/m2, day 1, CDDP 80 mg/m2, day 1) versus DG (DTX 100
mg/m2, day 8; GEM 1100 mg/m2, days 1 and 8) had similar
efficacy (response rate, 32.4% vs 30.2%) and survival data
(median survival time, 10 vs 9.5 months; 1-year survival rate,
42% vs 38%). Compared with the DC arm, the DG arm had
a more favorable toxicity profile. However, in their study, all
patients received prophylactic recombinant G-CSF. They also
conducted another randomized phase III trial (413 patients)
comparing DG with CDDP plus VNR (VC) with prophylactic
G-CSF support.25 Overall response rates were 30% and
39.2% (P  0.053) for the DG and VC arms, respectively.
Median survival time was 9.0 and 9.7 months (P 0.965) for
the DG and VC arms, respectively. Quality of life was
improved for the DG but not for the VC patients. The DG
regimen had a better toxicity profile. Pujol et al.26 also
demonstrated that a non–cisplatin-based regimen was as
effective as a cisplatin-based regimen. Their randomized
phase III study compared the efficacy, including progression-
free survival (PFS), and safety of DG regimen (DTX 85
mg/m2, day 8 plus GEM 1000 mg/m2, days 1 and 8) versus
VC regimen (VNR 30 mg/m2, days 1, 8, and 15 plus CDDP
100 mg/m2, day 1). A total of 311 patients were enrolled.
Objective response rates did not differ significantly (31% for
DG, 35.9% for VC). Neither PFS nor overall survival differed
significantly between the two arms (median PFS 4.2 and 4
months; median survival 11.1 and 9.6 months for DG and
VC, respectively). The VC arm experienced a higher number
of serious adverse events except pulmonary events and a
lower compliance with the protocol.
Several systematic reviews comparing cisplatin-based
and cisplatin-free chemotherapy doublet regimens in ad-
vanced NSCLC have been published. Platinum-free doublet
regimens based on third-generation drugs (i.e., VNR, DTX,
PTX, and GEM) yield a better efficacy/toxicity ratio and are
expected to offer the patients improved survival without
decreasing their quality of life.27–29 Recently, D’Addario et
al.30 performed a meta-analysis to compare the activity,
efficacy, and toxicity of platinum-based versus non–plati-
num-based chemotherapy among patients with advanced
NSCLC. A 62% increase in the odds ratio (OR) for response
was attributed to platinum-based therapy (OR, 1.62; 95% CI,
1.46-1.8; P 0.0001). No statistically significant increase in
1-year survival was found when platinum therapies were
compared with third-generation–based combination regi-
mens (OR, 1.11; 95% CI, 0.96-1.28; P 0.17). The toxicity
of platinum-based regimens was significantly higher for he-
matological toxicity, nephrotoxicity, and nausea and vomit-
ing. Thus, the role of cisplatin may be challenged by well-
tolerated third-generation combination regimens. These
modern combination regimens are valid options for patients
with advanced NSCLC.
The present randomized study was terminated early
because seven patients in the DG arm had grade 3 ILD.
Fortunately all patients were successfully treated with oxygen
and steroid treatment. The incidence rate of 11% in our study
was rather high, and ILD was only observed in the DG
regimen. Matsui et al.31 reported a result of a phase I/II study
comparing regimen schedules of GEM and DTX in Japanese
patients with stage IIIB/IV chemotherapy-naı¨ve NSCLC.
Grade 3 ILD was observed in three of 51 patients (5.9%) who
received GEM 1000 mg/m2, days 1 and 8 and DTX 50-60
mg/m2, day 1. The Japan Clinical Oncology Group conducted
a randomized study to compare DTX (D) with DTX plus
GEM (DG) for second-line treatment of NSCLC.32 One
hundred thirty patients were randomized to receive either D
(DTX 60 mg/m2, day 1) or DG (DTX 60 mg/m2, day 8, GEM
800 mg/m2, days 1, 8), repeated every 21 days until disease
progression. Their trial was terminated early with an unex-
pected high incidence of ILD (17%) and three treatment-
related deaths (5%) because of ILD only in DG arm. There
was no baseline risk factor for predicting ILD, except for
male gender. In our study, the incidence of ILD was appar-
ently greater among men (14.6%) than women (4.5%). How-
ever, there was no statistical difference between men and
women. The incidence of ILD was, however, reported to be
0% to 5.2% in other studies conducted on the same treatment
schedule in Europe17,19,25,26,33 The predisposing factor for
ILD might be related to ethnicity, as a high incidence of ILD
was observed in Japanese patients treated with gefitinib. The
incidence of ILD was apparently high among Japanese pa-
tients (3.2%–10%) compared with Euro-Americans (less than
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1%).34–37 The West Japan Thoracic Oncology Group ana-
lyzed 1,976 patients receiving gefitinib retrospectively.34 The
incidence of ILD was 3.2%, and the death rate resulting from
ILD was 1.3%. In this case, multivariate analyses also re-
vealed that risk factors included being male, individuals who
smoked, and complication of interstitial fibrosis among Jap-
anese patients.
ILD was also observed in a relatively high incidence
when DTX and GEM were administered weekly. Popa et al.17
reported a phase II trial of DG among patients with chemo-
therapy-naı¨ve, advanced NSCLC. Thirty-two patients were
treated with GEM (1000 mg/m2) and DTX (40 mg/m2) on
days 1 and 8 every 21 days. Six patients (18.7%) experienced
grade 3 pneumonitis that was at least possibly related to the
combination of DG. There was another phase I study that
reported a high incidence of ILD when chemotherapy-naı¨ve
patients with advanced NSCLC were treated with DG.38
Escalated dose of GEM and DTX were given on a weekly
basis for 3 consecutive weeks in cycles of 4 weeks. At the
dose of DTX 40 mg/m2 per week and GEM 1000 mg/m2 per
week, the study was prematurely closed because of a high
incidence of severe ILD. Six patients (23%) developed ILD,
which was fatal in two. No risk factors were identified
contributing to ILD. These reports seem to indicate that the
weekly administration of DTX and GEM in a relatively high
dose may be associated with a high incidence of pulmonary
adverse events.
As far as radiation is concerned, Popa et al.17 suggested
that there might be a predisposition to ILD among patients
who had previously received radiation therapy because five of
six patients in the study who developed treatment-related ILD
had previously received radiation therapy of the chest and
mediastinum. However, seven patients who developed ILD in
our study had no history of prior thoracic radiation. In the
case of the Georgoulias et al.,25 8 of 209 patients had previous
radiotherapy, and two patients developed grade 2 ILD. Al-
though only 2 of 155 patients had a history of thoracic
radiotherapy in Pujol et al.’s trial, eight patients experienced
ILD.26 Therefore, the exact mechanism by which it induces
severe ILD is not known.
In conclusion, the DG regimen had a response rate and
1-year survival rate comparable to that of the DC regimen,
and gastrointestinal toxicities were less frequent in the DG
regimen than in the DC regimen. The DG regimen used in the
present schedule and dose may induce pulmonary toxicity
and should be carefully administered in patients with ad-
vanced NSCLC.
ACKNOWLEDGMENTS
This study was funded by The Tokyo Cooperative On-
cology Group.
We thank Masahiro Takeuchi, Sc.D., M.P.H. (Division
of Biostatistics, Kitasato University Graduate School) for his
help with data analysis. The study management by Fulcrum
Pharma K.K. is also appreciated.
REFERENCES
1. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced
non-small cell lung cancer: a meta-analysis. Lancet 1993;343:19–21.
2. Grilli R, Oxaman AD, Julian JM. Chemotherapy for advanced non-small
cell lung cancer. How much benefit is enough? J Clin Oncol 1993;11:
1866–1872.
3. Marino P, Pampallona S, Prestoni A, et al. Chemotherapy versus
supportive care in advanced non-small cell lung cancer: results of a
meta-analysis of the literature. Chest 1994;106:861–865.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomized clinical trials. BMJ 1995;311:
899–909.
5. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus support-
ive care in advanced non-small cell lung cancer: improved survival
without detriment to quality of life. Thorax 2004;59:828–836.
6. Devita VT, Hellman S, Rosenberg SA. Cancer: Principle & Practice of
Oncology, 7th Ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
Pp. 796.
7. Cerny T, Kaplan A, Pavlides N, et al. Docetaxel (Taxotere) is active in
non-small-cell lung cancer: a phase II trial of the EORTC early clinical
trials group (ETCG). Br J Cancer 1994;70:384–387.
8. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in
previously untreated advanced non-small-cell lung cancer: a Japanese
cooperative study. J Clin Oncol 1996;14:1649–1655.
9. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treat-
ment of advanced non-small-cell lung cancer with docetaxel and cispla-
tin: a multicenter phase II study. Ann Oncol 1998;9:331–334.
10. Belani CP, Einzig A, Bonomi P, et al. Multicenter phase II trial of
docetaxel and carboplatin in patients with stage IIIB and IV non-small-
cell lung cancer. Ann Oncol 2000;11:673–678.
11. Schiller JH, Harrington D, Belani CP, et al. Comparison of four che-
motherapy regimens for advanced non-small cell lung cancer. N Engl J
Med 2002;346:92–98.
12. Fossella F, Pereira J, von Pawel J, et al. Randomized, multinational,
phase III study of docetaxel plus platinum combinations versus vinorel-
bine plus cisplatin for advanced non-small-cell lung cancer: the TAX
326 study group. J Clin Oncol 2003;21:3016–3024.
13. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of
docetaxel plus cisplatin versus vindesine plus cisplatin in patients with
stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer
Study Group. J Clin Oncol 2004;22:254–261.
14. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of
gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol
1994;12:1535–1540.
15. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine com-
bination in advanced non-small-cell lung cancer: a phase II study. J Clin
Oncol 1997;15:297–303.
16. Sander AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine
plus cisplatin versus cisplatin alone in patients with locally advanced or
metastatic non-small cell lung cancer. J Clin Oncol 2000;18:122–130.
17. Popa IE, Stewart K, Smith FP, et al. A phase II trial of gemcitabine and
docetaxel in patients with chemotherapy-naive advanced non-small cell
lung carcinoma. Cancer 2002;95:1714–1719.
18. Hirsh V, Whittom R, Desjardins P, et al. Docetaxel and gemcitabine
administered on days 1 and 8 for metastatic non-small cell lung carcinoma
(NSCLC): a phase II multicenter trial. Lung Cancer 2004;46:113–118.
19. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and
non-platinum-based chemotherapy in advanced non-small-cell lung can-
cer: a multicenter trial. Lancet 2001;357:1478–1484.
20. Miyazaki M, Takeda K, Mukaibara T, et al. A phase I/II study of
gemcitabine and docetaxel in advanced non-small cell lung cancer. Jpn
Soc Clin Oncol 2000;35:445.
21. Okamoto H, Watanabe K, Segawa Y, et al. Phase II study of docetaxel
and cisplatin in patients with previously untreated metastatic non-small-
cell lung cancer. Int J Clin Oncol 2000;5:316–322.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer Inst
2000;92:205–216.
23. Makuch R, Simon R. Sample size requirements for evaluating a conser-
vative therapy. Cancer Treat Rep 1978;62:1037–1040.
24. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized
phase II trial of gefitinib for previously treated patients with advanced
non-small-cell lung cancer. J Clin Oncol 2003;21:2237–2246.
25. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin
Katakami et al. Journal of Thoracic Oncology • Volume 1, Number 5, June 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer452
versus docetaxel plus gemcitabine in advanced non-small-cell lung
cancer: a phase III randomized trial. J Clin Oncol 2006;23:2937–2945.
26. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus
cisplatin-vinorelbine in advanced or metastatic non-small-cell lung can-
cer: a phase III study addressing the case for cisplatin. Ann Oncol
2006;16:602–610.
27. Pujol JL, Quantin X, Choma D, et al. Combination chemotherapy
without cisplatin in the treatment of advanced non-small cell lung
cancer. Lung Cancer 2002;38:S57–S60.
28. Barlesi F, Pujol JL. Combination of chemotherapy without platinum
compounds in the treatment of advanced non-small cell lung cancer: a
systematic review of phase III trial. Lung Cancer 2006;49:289–298.
29. Chu Q, Vincent M, Logan D, et al. Taxanes as first-line therapy for
advanced non-small cell lung cancer: a systematic review and practice
guideline. Lung Cancer 2006;50:355–374.
30. D’Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-
platinum-based chemotherapy in advanced non-small-cell lung cancer: a
meta-analysis of the published literature. J Clin Oncol 2006;23:2926–2936.
31. Matsui K, Hirashima T, Nitta T, et al. A phase I/II study comparing
regimen schedules of gemcitabine and docetaxel in Japanese patients
with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 2006;
35:181–187.
32. Takeda K, Negoro S, Tamura T, et al. Docetaxel (D) versus docetaxel
plus gemcitabine (DG) for second-line treatment of non-small cell lung
cancer (NSCLC): results of a JCOG randomized trial (JCOG0104)
(Abstract). Proc Am Soc Clin Oncol 2004;22:14S.
33. De Castro J, Lorenzo A, Morales S, et al. Phase II study of a fixed
dose-rate infusion of gemcitabine associated with docetaxel in advanced
non-small-cell lung carcinoma. Cancer Chemother Pharmacol 2006;55:
197–202.
34. Seto T, Yamamoto N. Interstitial lung disease induced by gefitinib in
patients with advanced non-small cell lung cancer: results of a West
Japan Thoracic Oncology Group (WJTOG) epidemiological survey. J
Clin Oncol 2004;22:632s.
35. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with
gefitinib in patients with advanced non-small-cell lung cancer: a phase II
study. J Clin Oncol 2006;24:64–69.
36. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination
with gemcitabine and cisplatin in advanced non-small-cell lung cancer:
a phase III trial-INTACT 1. J Clin Oncol 2004;22:777–784.
37. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with
paclitaxel and carboplatin in advanced non-small-cell lung cancer: a
phase III-INTACT 2. J Clin Oncol 2004;22:785–794.
38. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of
pulmonary toxicity of weekly docetaxel and gemcitabine in patients with
non-small cell lung cancer: results of a dose-finding study. Lung Cancer
2004;44:363–368.
Journal of Thoracic Oncology • Volume 1, Number 5, June 2006 DC vs. DG for Advanced NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 453
